EA201070467A1 - Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом - Google Patents

Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом

Info

Publication number
EA201070467A1
EA201070467A1 EA201070467A EA201070467A EA201070467A1 EA 201070467 A1 EA201070467 A1 EA 201070467A1 EA 201070467 A EA201070467 A EA 201070467A EA 201070467 A EA201070467 A EA 201070467A EA 201070467 A1 EA201070467 A1 EA 201070467A1
Authority
EA
Eurasian Patent Office
Prior art keywords
soamorph
modification
compound
compositions obtained
solid condition
Prior art date
Application number
EA201070467A
Other languages
English (en)
Other versions
EA023338B1 (ru
Inventor
Тодд Ф. Овокайтис
Джон Скотт Страчан
Original Assignee
Тодд Ф. Овокайтис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тодд Ф. Овокайтис filed Critical Тодд Ф. Овокайтис
Publication of EA201070467A1 publication Critical patent/EA201070467A1/ru
Publication of EA023338B1 publication Critical patent/EA023338B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Данное изобретение относится к способу получения некристаллических органических композиций и некристаллических, соаморфных смесей органических соединений.
EA201070467A 2007-10-17 2008-10-16 Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом EA023338B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99948307P 2007-10-17 2007-10-17
US99946207P 2007-10-17 2007-10-17
US99944507P 2007-10-17 2007-10-17
US12/252,458 US8173632B2 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
PCT/US2008/080095 WO2009052246A1 (en) 2007-10-17 2008-10-16 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same

Publications (2)

Publication Number Publication Date
EA201070467A1 true EA201070467A1 (ru) 2011-06-30
EA023338B1 EA023338B1 (ru) 2016-05-31

Family

ID=40567777

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070467A EA023338B1 (ru) 2007-10-17 2008-10-16 Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом

Country Status (10)

Country Link
US (1) US8173632B2 (ru)
EP (1) EP2211611B1 (ru)
JP (1) JP5596547B2 (ru)
CN (1) CN101969766B (ru)
BR (1) BRPI0818575A2 (ru)
CA (1) CA2702903C (ru)
EA (1) EA023338B1 (ru)
IL (1) IL205155A (ru)
WO (1) WO2009052246A1 (ru)
ZA (1) ZA201003353B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702909C (en) * 2007-10-17 2016-05-10 Todd F. Ovokaitys Room temperature stable non-crystalline aspirin
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
CN103360357B (zh) * 2013-08-07 2015-07-22 中国药科大学 辛伐他丁格列齐特共无定型物
CN104415042A (zh) * 2013-08-30 2015-03-18 天津药物研究院 一种共无定型系统及其制备方法
CN103923049A (zh) * 2014-05-05 2014-07-16 武汉远瞩医药科技有限公司 黄芩素咖啡因共无定型物
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
US11453840B2 (en) * 2018-04-28 2022-09-27 John Anton Broadhurst Method for applying energy to cannabidiol
JPWO2020262455A1 (ru) * 2019-06-25 2020-12-30

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525103D0 (en) * 1995-12-08 1996-02-07 Strachan John S Optical device and method of manufacture
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
IT1312115B1 (it) * 1999-06-24 2002-04-04 Nicox Sa Composti amorfi e relative composizioni farmaceutiche
GB9920351D0 (en) * 1999-08-28 1999-11-03 Strachen John S Sparse constructive node stimulation of cell surface molecular resonance in vivo
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
CZ292832B6 (cs) * 2001-08-30 2003-12-17 Ivax Pharmaceuticals S.R.O. Způsob přípravy silymarinu se zvýšenou rozpustností
CA2459241C (en) * 2001-09-21 2010-07-13 Solvias Ag Sealing system with flow channels
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
WO2004071435A2 (en) 2003-02-10 2004-08-26 Todd Ovokaitys Enhanced Bioavailability Using Laser Resonant Homogenization
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
WO2007100614A2 (en) * 2006-02-24 2007-09-07 Scidose, Llc STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR

Also Published As

Publication number Publication date
EA023338B1 (ru) 2016-05-31
EP2211611A4 (en) 2012-03-28
EP2211611B1 (en) 2014-12-10
US8173632B2 (en) 2012-05-08
IL205155A0 (en) 2010-11-30
JP5596547B2 (ja) 2014-09-24
CA2702903C (en) 2016-01-19
IL205155A (en) 2017-12-31
US20090131376A1 (en) 2009-05-21
ZA201003353B (en) 2011-12-28
EP2211611A1 (en) 2010-08-04
CA2702903A1 (en) 2009-04-23
CN101969766B (zh) 2015-05-06
WO2009052246A1 (en) 2009-04-23
BRPI0818575A2 (pt) 2014-10-07
CN101969766A (zh) 2011-02-09
JP2011500709A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
EA201070467A1 (ru) Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1123658T1 (el) Μεθοδος για τη δημιουργια χημικων ενωσεων κινολονης
EA201000883A1 (ru) Производные индолинона и способ их получения
GEP20156266B (en) Spiroheterocyclic n-oxypiperidines as pesticides
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201590979A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
UA110600C2 (uk) Спосіб отримання захищених похідних l-аланіну
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
NZ593874A (en) Nalmefene hydrochloride dihydrate
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
EA201100517A1 (ru) Способ получения дабигатрана и его промежуточные соединения
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EA200870038A1 (ru) Способ получения аминов
MX2009006943A (es) Procedimiento para la mejor utilizacion del potencial de produccion de plantas transgenicas.
EA201200820A1 (ru) Способ синтеза промежуточных продуктов, применимых для получения замещенных индазолов и азаиндазолов
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
CR20110111A (es) Composicion farmaceutica solida

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU